LONDON – Verona Pharma plc published data showing its dual action bronchodilator, ensifentrine (RPL-554), can provide additional benefits for chronic obstructive pulmonary disorder (COPD) patients who are considered to be achieving maximum bronchodilation from existing dual or triple therapies.